New combo therapy shows promise in controlling advanced liver cancer
NCT ID NCT03033446
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink tumors and improve survival. The treatment aims to control the disease rather than cure it, as patients may need ongoing management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre - Singapore
Singapore, 169610, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?